Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-06-01T01:38:03.401Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of 2 Clostridium difficile Surveillance Methods National Healthcare Safely Network's Laboratory-Identified Event Reporting Module versus Clinical Infection Surveillance

Published online by Cambridge University Press:  02 January 2015

Kathleen A. Gase ,
Valerie B. Haley ,
Kuangnan Xiong ,
Carole Van Antwerpen  and
Rachel L. Stricof
Kathleen A. Gase*
Affiliation:
Bureau of Healthcare-Associated Infections, New York State Department of Health, Albany, New York
Valerie B. Haley
Affiliation:
Bureau of Healthcare-Associated Infections, New York State Department of Health, Albany, New York
Kuangnan Xiong
Affiliation:
Bureau of Healthcare-Associated Infections, New York State Department of Health, Albany, New York
Carole Van Antwerpen
Affiliation:
Bureau of Healthcare-Associated Infections, New York State Department of Health, Albany, New York
Rachel L. Stricof
Affiliation:
Bureau of Healthcare-Associated Infections, New York State Department of Health, Albany, New York Council of State and Territorial Epidemiologists, Atlanta, Georgia
*
4252 McPherson Avenue, St. Louis, MO 63108 (kathleen.gase@gmail.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To determine whether the Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN) laboratory-identified (LabID) event reporting module for Clostridium difficile infection (CDI) is an adequate proxy measure of clinical CDI for public reporting purposes by comparing the 2 surveillance methods.

Design.

Validation study.

Setting.

Thirty New York State acute care hospitals.

Methods.

Six months of data were collected by 30 facilities using a clinical infection surveillance definition while also submitting the NHSN LabID event for CDI. The data sets were matched and compared to determine whether the assigned clinical case status matched the LabID case status. A subset of mismatches was evaluated further, and reasons for the mismatches were quantified. Infection rates determined using the 2 definitions were compared.

Results.

A total of 3,301 CDI cases were reported. Analysis of the original data yielded a 67.3% (2,223/3,301) overall case status match. After review and validation, there was 81.3% (2,683/3,301) agreement. The most common reason for disagreement (54.9%) occurred because the symptom onset was less than 48 hours after admission but the positive specimen was collected on hospital day 4 or later. The NHSN LabID hospital onset rate was 29% higher than the corresponding clinical rate and was generally consistent across all hospitals.

Conclusions.

Use of the NHSN LabID event minimizes the burden of surveillance and standardizes the process. With a greater than 80% match between the NHSN LabID event data and the clinical infection surveillance data, the New York State Department of Health made the decision to use the NHSN LabID event CDI data for public reporting purposes.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 34 , Issue 3 , March 2013 , pp. 284 - 290
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Bartlett, JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002;346:334–339.Google Scholar
2. McDonald, LC, Owings, M, Jernigan, D. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409–415.Google Scholar
3. Archibald, LK, Banerjee, SN, Jarvis, WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004;189:1585–1589.Google Scholar
4. Ricciardi, R, Rothenberger, DA, Madoff, RD, Baxter, NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007;142:624–631.Google Scholar
5. Redelings, M, Sondilo, F, Mascola, L. Increase in Clostridium difficile–related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007;13:1417–1419.Google Scholar
6. Lucado, J, Gould, C, Elixhauser, A. Clostridium difficile Infections (CDI) in Hospital Stays, 2009. HCUP statistical brief no. 124. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/sbl24.pdf. Accessed April 2, 2012.Google Scholar
7. Hall, AJ, Curns, AT, McDonald, LC, Parashar, UD, Lopman, BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012;55:216–223.CrossRefGoogle ScholarPubMed
8. Dubberke, ER, Reske, KA, Olsen, MA, McDonald, LC, Fraser, VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008; 46:497–504.Google Scholar
9. McDonald, LC, Coignard, B, Dubberke, E, Song, X, Horan, T, Kutty, PK; Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. infect Control Hosp Epidemiol 2007;28:140–145.Google Scholar
10. Multidrug-resistant organism and Clostridium difficile infection (MDRO/CDI) module. National Healthcare Safety Network website, http://www.cdc.gov/nhsn/mdro_cdad.html. Accessed January 10, 2012.Google Scholar
11. New York State Department of Health. Hospital-Acquired Infections: New York State 2010. Albany: New York State Department of Health, 2011. http://www.health.ny.gov/statistics/facilities/hospital/hospital_acquired_infections/2010/docs/hospital_acquired_infection.pdf. Accessed May 21, 2012.Google Scholar
12. Campbell, RJ, Giljahn, L, Machesky, K, et al. Clostridium difficile in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol 2009;30:526–533.CrossRefGoogle ScholarPubMed
13. California Department of Public Health. Healthcare-Associated Clostridium difficile Infections in California Hospitals, January 2009 through March 2010. Sacramento: California Department of Public Health, 2011. http://www.cdph.ca.gov/programs/hai/Documents/HAIReportSB-1058Cdiff-FINAL.pdf. Accessed May 21, 2012.Google Scholar
14. Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and FY 2012 rates; hospitals' FTE resident caps for graduate medical education payment. Centers for Medicare and Medicaid Services website, http://www.naph.org/Main-Menu-Category/Our-Work/Safety-Net-Financing/Medicare/IPPS/FY2012-Final-IPPS-Rule.aspx?FT=.pdf. Accessed April 2, 2012.Google Scholar
15. Koll, BS, Ruiz, RE, Calfee, DP, et al. Prevention of hospital-onset Clostridium difficile infection in the New York metropolitan region using a collaborative intervention model. J Healthc Qual doi:10.111l/jhq.12002. Electronically published January 7,2012.Google Scholar
16. SPARCS overview. New York State Department of Health website, http://www.health.ny.gov/statistics/sparcs/operations/overview.htm. Accessed September 12, 2011.Google Scholar
17. Little, RJA, Rubin, DB. Statistical Analysis with Missing Data. Hoboken, NJ: Wiley, 2002.Google Scholar
18. Dallai, RM, Harbrecht, BG, Boujoukas, AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363–372.Google Scholar
19. McDonald, LC, Killgore, GE, Thompson, A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile . N Engl J Med 2005;353:2433–2441.Google Scholar
20. Dubberke, ER, Reske, KA, Olsen, MA, McDonald, LC, Fraser, VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008; 46:497–504.CrossRefGoogle Scholar
21. McGlone, SM, Bailey, RR, Zimmer, SM, et al. The economic burden of Clostridium difficile . Clin Microbiol Infect 2012;18(3): 282–289.Google Scholar